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Background: Transforming growth factor-β1 (TGF-β1) plays a key role in mesothelial-to-mesenchymal transition
(MMT) during peritoneal dialysis (PD). However, the role of Akt in MMT transformation in PD is not clear.
Results: In this study, we observed that the phosphorylated form of protein kinase B (Akt), termed as pAkt, was
up-regulated in the peritoneum of mice undergoing PD. It was associated with thickening of the peritoneum and
up-regulation of TGF-β1. Upregulation of pAkt paralleled with the increased expression of Smad ubiquitination regulatory
factor 2 (Smurf2), Vimentin and fibronectin (FN), and decreased expression of mothers against decapentaplegic homolog
7 (Smad7) and Zonula Occludens protein 1(ZO-1) in mice undergoing PD treatment and in TGF-β1 induced human
peritoneal mesothelial cells (HPMCs). These changes were reversed with the treatment of a PI3K/Akt inhibitor LY294002
in vivo or in cells transfected with Akt dominant-negative (Akt-DN) plasmids in vitro. Increased Smurf2 expression in
HPMCs, induced by TGF-β1 was accompanied with altered expression of Transforming growth factor receptor I (TβR-I),
Smad7, ZO-1, Vimentin and FN via Akt modulation. In addition, inhibition of Ubiquitin carboxyl-terminal hydrolase 4
(USP4) decreased TGF- β1-induced expression of TβR-I and reversed the altered expression of Smad7, Smurf2, ZO-1 and
Vimentin. Moreover, TGF-β1 accentuated the interactions between Smurf2 and Smad7, while reduced the association
between TβR-I and Smurf2. These interactions were reversed by the treatment of Akt-DN and USP4 siRNA, respectively.
Conclusions: These data implied that Akt mediated MMT in PD via Smurf2 modulation/and or Smad7 degradation
while conceivably maintaining the TβRI stability, most likely by the USP4.
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Continuous ambulatory peritoneal dialysis (CAPD) is an
alternative therapy to hemodialysis for the treatment of
end-stage renal disease. During CAPD, the peritoneum
is exposed to bio-incompatible dialysis fluids that cause
peritoneal fibrosis (PF) by denudation of mesothelial
cells. Thus, PF is a common morphological change in
peritoneal dialysis (PD) patients and in PD animal
models [1]. This change is associated with impaired peri-
toneal membrane function, ultrafiltration failure culmin-
ating into discontinuation of dialysis [2]. Furthermore,* Correspondence: liufuyoukidney@163.com; sunlinnwu11@163.com
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unless otherwise stated.epithelial-mesenchymal transition (EMT) of peritoneal
mesothelial cells (termed as MMT) plays a crucial initi-
ating role in the progression of PF [3]. Many factors,
including high glucose (HG), hypertonicity, low pH,
glucose degradation products and advanced glycation
end-products (AGEs) can induce Transforming growth
factor-β1 (TGF-β1) activation, and blocking of TGF-β1
signaling protects the peritoneal membrane from
dialysate-induced damage [4,5]. Therefore, TGF-β1 has
been regarded as the primary regulator and plays a
central role in MMT and fibrosis of peritoneal tissue
during PD.
Recent studies suggest that phosphatidylinositol 3-kinase
kinase (PI3K) /AKT signaling not only plays an important
role in the regulation of cell survival, growth, metabolismis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ation that may be independent of TGF-β1/Smad signaling
[7]. In addition, PI(3)K/AKT activation induced by TGF-β
through the direct binding of Type I transforming growth
factor receptor (TβRI) to PI(3)K [8] is related to increased
ECM protein expression [9]. Furthermore, TGF-β1 in-
duces fibrosis in various cell lines including human lung
cancer cells, hepatocellular carcinoma and renal proximal
tubule cells via the PI3K/Akt signaling pathways [10-12].
On the other hand, it has been reported that Akt modu-
lates E3 ubiquitin ligase, such as the transcription of
Smad7 ubiquitination regulatory factor2 (Smurf2) that is
induced by TGF-β1 [13], indicating that TGF-β1/Akt/
smurf2 pathway may play a critical role in some patho-
physiological conditions. Furthermore, it has been re-
ported that Smurf2 contributes to a reduction of Smad7
in fibrosing UUO kidneys [14]. The Smurf2 levels have
been reported to be increased in early period of fibrosis in
rat liver and TGF-β1-treated LX-2 cells, and they are ac-
companied with reduced levels of Smad7 [15]. Thus, it
seems that Smad7 provides a negative feedback to TβR1
by binding to Smurf2 and brings Smurf2 to the activated
TβR for their polyubiquitination and degradation [16].
This would indicate that decreased levels of Smad7 may
lead to activation of TGF-β1 signaling. It has been demon-
strated that Smad7 expression is decreased in peritoneum
of PD patients. Overexpression of Smad7 inhibits Smad2/
3 activation and the EMT related protein expression,
extracellular matrix protein (ECM) and fibrosis in the
peritoneal mesothelial cells and animal models of PD
[17-19]. Whether Akt induces Smurf2 expression and
then inhibits Smad7 participation in MMT transformation
during PD and the relevant mechanism(s) involved have
not been thoroughly explored.
The TGF-β receptors (TβR) play a key role in TGF-β
signaling pathway, which is targeted for ubiquitylation-
mediated degradation by the Smad7/Smurf2 complex
[20]. Emerging studies have demonstrated that deubi-
quitinating enzymes (DUBs) play a key role for main-
taining TβRI stability. Among of them, ubiquitin-
specific peptidase-4 (USP4) and-15 (USP15) extend the
life of activated TβRI and are against the negative pres-
sure of TβRI-ubiquitinating complexes [16,21]. Interest-
ingly, it was also found that Akt directly associates and
phosphorylates USP4, and then induces the translo-
cation of USP4 from the nucleus to the cytoplasm
and plasmalemma for maintaining TβRI stability [22].
Therefore, USP4 mediates TβRI regulation via PI3K/
Akt pathway, which is a strong modulator of TGF-β
pathway and plays a critical role in the crosstalk be-
tween TGF-β and AKT signaling. Whether Akt mediates
MMT transformation in PD fibrosis and the mechanism
(s) by which USP4 is involved in this process has yet to
be elucidated.In the present study, we investigated that if increased
activation of Akt exerts a critical effect on TGF-β1 in-
duced MMT in PD via Smurf2/Smad7 complex and
USP4/TβRI pathway.Results
Expression of TGF-β1 and p-Akt, Smurf2 and Smad7 in
PD mice
ELISA assay showed that the concentration of TGF-β1
increased in the peritoneal effluent of PD mice com-
pared to control (P < 0.01), while there are no further
significant changes in mice treated with the PI3K/Akt
inhibitor, LY294002 (Figure 1A). By real-time PCR, an
up-regulated expression of smurf2 mRNA was ob-
served in the peritoneal tissues of PD mice, while it
was dramatically down-regulated in mice treated with
LY294002 (Figure 1B). Confocal imaging with Anti-
phospho-Akt1 (Ser473/Tyr474) antibody (anti-pAkt)
showed that there was a low level of phosphorylated
Akt (pAkt) expression in the peritoneum of control
mice and it markedly increased in PD mice. The expres-
sion was significantly inhibited by LY294002 (Figure 1C,
left panels). Like the pAkt, a parallel increase in the
Smurf2 levels was also observed (Figure 1C, right
panels). In addition, Western blot analyses revealed
that the protein expression of pAkt (Figure 1D, upper
panels, D1) and Smurf2 (Figure 1D, lower panels, D3)
were markedly increased in PD mice compared to con-
trol, which was reversed by treatment with LY294002.
In contrast, a decreased expression of Smad7 protein
was seen in PD mice, and Smad7 expression was re-
stored by the treatment with LY294002 (Figure 1D,
middle panels, D2).Inhibition of Akt normalizes the altered expression of ZO-1,
Vimentin and fibrosis in the peritoneum of PD mice
Morphological changes in the peritoneum were assessed
by H & E and Masson staining. The thickness of the
sub-mesothelial tissue in the peritoneum of PD mice in-
creased approximately 4–5 times compared to control,
whereas, it was dramatically attenuated in mice treated
with LY294002 (Figure 2A and 2A1). In addition, by real
time PCR, Vimentin and fibronectin (FN) mRNA ex-
pression in the peritoneal tissue of PD mice were signifi-
cantly increased, which was accompanied with markedly
decreased mRNA expression of ZO-1. However, treat-
ment with LY294002 led to a significant normalization
of their expression (Figure 2B, B1-B3). Similar results
were observed for the protein expression by tissue image
analysis with immunofluorescence microscopy (Figure 2C),
which were confirmed byWestern blot analyses (Figure 2D
and 2E, E1-E3).
Figure 1 Expression of TGF-β1, pAkt, Smurf2 and Smad7 in mice undergone peritoneal dialysis (PD) and the modulation of Smurf2
and Smad7 expression by PI3/Akt inhibitor (LY294002). Panel A: Bar graphs represent the summary of TGF-β1 concentration in the PD effluent
in each group, as measured by ELISA method. Panel B: Real-time PCR showing increased mRNA expression of Smurf2 in the peritoneal tissue of PD
mice, whereas it was inhibited by the treatment with PI3/Akt inhibitor LY294002. Panel C: Immunofluorescence microscopy of peritoneal tissue stained
with either specific anti-pAkt or anti-Smurf2 antibodies (red) and counter stain with DAPI (blue). Increased immuno-reactive signals representing
expression of pAkt and Smurf2 were observed in the peritoneum of PD mice and were markedly decreased with the LY294002 treatment
(original magnifications × 200). Panel D: The expression of pAkt, Smad and Smurf2 in the peritoneal tissue of PD mice, as assessed by Western
blot analyses. Panels D1-D3: The bar graphs represent the densitometric measurements of Western blot bands. Values are the mean ± SEM,
n = 5, * p <0.01 vs. control, # p <0.01 vs. PD group.
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MMT-relevant proteins and down-regulates Smad7
expression in HPMCs
HPMCs were exposed to different concentrations of
TGF-β1 (0–10 ng/ml) for 48 hrs. By real time PCR, a
significant dose dependent decrease in the mRNA ex-
pression of ZO-1 was observed. In contrast, the mRNAexpression of Vimentin and Smurf2 were increased mark-
edly in a dose dependent manner (Figure 3A). Western
blot analyses showed that a dose-dependent up-regulated
expression of pAkt and Smurf2 in HPMCs following
stimulation with TGF-β1, while the expression of Smad7
protein was significantly down-regulated. In addition, a
decreased expression of ZO-1 and an increased expression
Figure 2 PI3K/Akt inhibitor normalized MMT relevant proteins’ expression and peritoneal fibrosis in PD mice model. Panel A:
Hematoxylin-Eosin (top panels) and Masson’s Trichrome staining (bottom panels) of the parietal peritoneum in control mice, PD mice with or
without LY294002 treatment. Panel A1: Semi quantification of H & E staining for the thickness of the sub-mesothelial tissue of the parietal peritoneum.
Panels B1 - B3: Bar graphs represent the mRNA expression of ZO-1, Vimentin and fibronectin (FN) in peritoneal tissues, as detected by real-time PCR.
Panel C: Immunofluorescence microscopy of the peritoneal tissue sections following staining with ZO-1 (red) and Vimentin (green) antibodies.
Treatment with LY294002 restored the expression of ZO-1 to a certain extent and inhibited the over-expression of Vimentin in the peritoneum
compared to PD mice. Panel D: Western blot analysis showed the expression of ZO-1, Vimentin and FN. Panels D1-D3. Panels E1-E3: Bar
graphs represent the densitometric measurements of the bands seen by Western blot analyses. Values are the mean ± SEM, n = 6, * p <0.01
vs. control group, # p <0.01 vs. PD group.
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Figure 3 Expression of EMT/MMT relevant protein, fibronectin, smurf2, Smad7 and pAkt in HPMCs following TGF-β1 treatment. Panel A:
By Real-time PCR, a dose-dependent decrease in mRNA expression of ZO-1 was seen in HPMCs treated with TGF-β1, while an increased expression of
Vimentin and Smurf2 miRNA was observed. Panel B: Western blot analyses showed that the protein expression of ZO-1 and Smad7 was decreased
with a dose-dependent manner in HPMCs treated with TGF-β1. In contrast, the expression of Vimentin, pAkt and Smurf2 was significantly increased.
Panel C: The bar graphs represent the densitometric measurements of the bands seen by Western blotting procedures. Panel D: The bar graph
represents the fibronectin concentration in the supernatant of cultured HPMCs induced by TGF-β1 and detected By ELISA. Values are the
mean ± SEM, n = 6, * p <0.01 vs. control.
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(Figure 3B and 3C, C1-C5). Furthermore, by ELISA, a
dose-dependent increased protein concentration of FN
was noted in HPMCs exposed to TGF-β1 (Figure 3D).
To delineate the role of TGF-β1 in the gene and pro-
tein expression of above indicated molecules with time
course, HPMCs were incubated with 5 ng/ml TGF-β1
for 0–72 hrs. As shown in Figure 4A-4C, ZO-1 mRNA
expression was significantly decreased in a time dependentmanner (Figure 4A), while that of Vimentin expression
was increased (Figure 4B). Interestingly, the smurf2 ex-
pression showed a dramatically increase up to 12–48 hrs
and then it was somewhat reduced but did not reach to
the basal levels (Figure 4C). Confocal image of cell im-
munofluorescence clearly showed an enhanced pAkt nu-
clear expression in HPMCs after incubation with TGF-β1
for 15 min, and it increased a little bit further at 30 min
(Figure 4D, upper panels). The expression of Smurf2 was
Figure 4 Effect of TGF-β1 on the expression of pAkt, ZO-1, Vimentin, Smurf2 and Smad7 in HPMCs, as assessed by Real-time PCR
(Panels A-C), Cell Immuno- fluorescence (Panels D and E) and Western blot assay (Panels F, G & H1-H4). The bar graphs show a
time-dependent mRNA expression of ZO-1 (Panel A), Vimentin (Panel B) and Smurf2 (Panel C) in HPMCs after treatment with TGF-β1 (5 ng/ml)
for 0–72 hrs. Panels D and E: Confocal images of cells after staining with anti-pAkt, −Smurf2, −ZO-1 and -Vimentin antibodies. An increased
nuclear expression of pAkt was observed in HPMCs following treatment with 5 ng/ml of TGF-β1 for 30 min (Panel D, upper panels). The Smurf2
expression in cytoplasm was also significantly increased (Panel D, lower panels). The ZO-1 expression was decreased in a time-dependent manner
in HPMCs following treatment with TGF-β1 for 48 hr, which further decreased at 72 hr (Panel E, upper panels), In contrast, Vimentin expression
was increased (Panel E, lower panels). Panel F & G: Western blot analyses of protein extract from HPMCs showed that pAkt and smurf2 expression
initially increased in HPMCs, and then gradually decreased. While ZO-1 and Smad7 expression was gradually decreased over time. The Vimentin
expression was significantly increased gradually over time. Panel H: The bar graphs represent the band density of Western blots. Values are the
mean ± SEM, n = 3, * p <0.01 vs. control.
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TGF-β1 for 12 hrs, and it peaked at 24 hrs (Figure 4D,
lower panels). Additionally, a significant decreasedimmunofluorescence signal in the cell membrane,
depicting ZO-1 expression, was observed in HPMCs
treated with TGF-β1at 48 hrs, and it further decreased
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sion increased in a time-dependent manner (Figure 4E,
lower panels). By Western blot analyses, pAkt protein ex-
pression was increased significantly in HPMCs treated
with TGF-β1 for 30 min, and then it gradually decreased
but did not reach to the basal levels (Figure 4F, upper
panels and 4H, H1). Similar expression profiles were also
observed for the Smurf2 protein where it peaked at 24 hrs
(Figure 4G, lower panels and 4H, H4). The ZO-1 and
Smad7 expression was significantly decreased in a time-
dependent manner up to 72 hrs (Figure 4G and 4H, H3);
and in contrast, Vimentin expression was increased
(Figure 4G, middle panels and 4H, H2).
Akt inhibited TGF-β1-induced expression of MMT relevant
proteins in HPMCs
Real- time PCR showed that ZO-1 mRNA expression
decreased significantly in HPMCs treated with TGF-β1,
while it was partially restored by the treatment with
LY294002 or by transfection of with an Akt-dominant
negative plasmid (Akt-DN) (Figure 5A), In addition, op-
posite results were observed for Vimentin mRNA expres-
sion (Figure 5B). By immunofluorescence microscopy,
HPMCs stained with anti-pAkt, −ZO-1, −Vimentin anti-
bodies yielded parallel results. TGF-β1 significantly in-
creased the expression of pAkt, while it was reversed with
the treatment of LY294002 or over-expression of Akt-DN
(Figure 5C upper panels). Additionally, cells treated with
LY294002 or Akt-DN had normalized altered ZO-1 and
Vimentin expression in HPMCs concomitantly treated
with TGF-β1 (Figure 5C middle and lower panels). Fur-
thermore, by Western blot analysis, an increased expres-
sion of pAkt in the nuclear extract from HPMCs treated
with TGF-β1 was observed, while it was reduced in cells
transfected with Akt-DN plasmid, while no significant
change was seen in the total Akt expression (Figure 5D).
On the other hand, pAkt expression was decreased in
cytoplasmic extract from HPMCs treated with TGF-β1,
while normalized following treatment with LY294002 or
Akt-DN (Figure 5E, upper panels and 5F, F1), as detected
by Western blot analyses. Similar results were also ob-
served in the EMT/MMT relevant proteins such as
Vimentin expression (Figure 5E, lower panels and 5F, F3).
In contrast, ZO-1 protein expression was noted to be de-
creased in HPMCs treated with TGF-β1. However, the ef-
fect was partially blocked by the treatment with LY294002
or Akt-DN (Figure 5E, middle panels, and 5F, F2).
Effect of Akt on the expression of Smurf2 and Smad7
Real-time PCR revealed that mRNA expression of
Smurf2 significantly increased in HPMCs treated with
TGF-β1, while the expression was blocked partially in a
dose-dependent manner either by the treatment with
LY294002 or transfection with Akt-DN mutant plasmid(Figure 6A). Western blot analyses showed that the
Smad7 protein expression was significantly inhibited in
HPMCs incubated with TGF-β1, while it was restored
partially by the treatment with either LY294002 or
transfection with an Akt-DN (Figure 6B and 6C, C1).
In contract, the Smurf2 expression was increased in
HPMCs treated with TGF-β1, while it was reduced in
cells treated with Y294002 or transfection with an Akt-
DN (Figure 6B and 6C, C2). In addition, the up-
regulated expression of Smurf2 was confirmed by im-
munofluorescence microscopy following the staining
with anti-Smurf2 antibody. Interestingly, Akt-DN only
partially inhibited the TGF-β-induced Smurf2 expres-
sion (panel on the extreme right, Figure 6D) while
completely with LY294002 (panel next to TGF-β1,
Figure 6D).
Effect of Akt, Smurf2 and USP4 on the expression of
ZO-1, Vimentin and Fibronectin in HPMCs incubated with
TGF-β1
By real-time PCR, a significantly decreased mRNA ex-
pression of ZO-1 was seen in HPMCs incubated with
TGF-β1 or transfected with Flag-Akt plasmid (Figure 7A,
lanes 2 and 5 vs lane 1), while no affect was seen in cells
treated with Smurf2 siRNA and USP4 siRNA (Figure 7A,
lanes 3, 4 vs lane 1). TGF-β1 reduced ZO-1 mRNA ex-
pression, which was restored following concomitant
treatment with Smurf2 siRNA and USP4 siRNA
(Figure 7A, lanes 6 and 7 vs lane 2). In addition, ZO-1
expression was decreased by TGF-β1 plus Flag-Akt
treatment (Figure 7A, lane 8 vs lane 2), and it was par-
tially restored by transfection of Smurf2 siRNA or USP4
siRNA (Figure 7A, lanes 9 and 10 vs lane 8). In contrast,
opposite results were observed for the Vimentin mRNA
expression (Figure 7B). Similar results were also seen
for the protein expression of ZO-1 and Vimentin, as de-
tected by Western blot procedures (Figure 7C and 7D,
D1 and D2). Fibronectin (FN) protein expression in
HPMCs was also measured by ELISA. An increased FN
expression was seen in HPMCs exposed to TGF-β1 or
transfected with Flag-Akt (Figure 7D, lanes 2 and 5 vs
lane 1). No change in the FN expression was observed
in cells treated with Smurf2 siRNA or USP4 siRNA
alone compared to basal levels. The effect of TGF-β1 on
the expression of FN was partially blocked by the treat-
ment with Smurf2 siRNA or USP4 siRNA (Figure 7D,
lanes 6 and 7 vs lane 2), but was further augmented with
transfection of Flag-Akt. In addition, Smurf2 siRNA and
USP4 siRNA reduced the up-regulated expression of FN
in HPMCs induced by TGF-β1plus Flag-Akt (Figure 7D,
lanes 9 and 10 vs lane 8). Compared to controls, the
mRNA and protein expression did not change in cells
treated with scrambled siRNAs (data not shown - space
limitations).
Figure 5 (See legend on next page.)
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Figure 6 Expression of Smurf2 and Smad7 in HPMCs following exposure to TGF-β with/without treatment of LY294002 and Akt-DN.
Panel A: Bar graph represents the summary of Smurf2 mRNA expression, as detected by Real-time PCR analyses. Panel B: Represents of Smurf2
and Smad7 expression profiles following treatment of LY294002 or transfected with Akt-DN, as assessed by Western blot analyses. The β-actin
served as a loading control. Panel C: The bar graphs represent the relative bands density of Smad7 (Panel C1) and Smurf2 (Panel C2) of Western
blots. A decreased expression of Smad7 was observed in HPMCs incubated with TGF-β1, while the effect was abolished by the pre-treatment with
LY294002 and transfection with Akt-DN, in addition, TGF-β1 significantly up-regulated the expression of Smurf2, which was inhibited with Akt-DN
or LY294002. Panel D: Immunofluorescence microscopy revealed that TGF-β1 significantly increased Smurf2 expression in HPMCs, which was
dramatically decreased by LY294002 (next to the extreme right panel), but only partially attenuated by transfection with Akt-DN (extreme right
panel). Values are the mean ± SEM, n = 5, * p <0.01 vs control, # p <0.01 vs TGF-β1.
(See figure on previous page.)
Figure 5 Effect of Akt-DN and LY294002 on ZO-1 and Vimentin expression in HPMCs. Panels A and B represent summary of Real-time
RT-PCR. A reduced mRNA expression of ZO-1 (Panel A) and increased that of Vimentin (Panel B) in HPMCs stimulated with TGF-β1 was observed,
while the expression was partially restored to pre-treatment levels with the PI3K inhibitor, LY294002 or by transfection of dominant-negative Akt
(Akt-DN) plasmid. Panel C: By immunofluorescence microscopy, down-regulated ZO-1 and up-regulated Vimentin expression was observed in
HPMCs subjected to TGF-β1 treatment, and it was normalized with transfection with Akt-DN or pretreatment with LY294002. On the other hand,
TGF-β1 induced pAkt translocation to the nucleus in HPMCS, while partially blocked by treatment with either Akt-DN and LY294002. Similar results
were also observed in nuclear extract from HPMCs, as detected by Western blot analyses (Panel D, D1-D2). Panel E: Western blot analyses
showed down- regulated ZO-1 expression in HPMCs stimulated with TGF-β1, while partially reversed in that of treatment with LY294002 or
Akt-DN plasmid. In contrast, an up-regulated Vimentin and pAkt expression was seen in HPMCs stimulated with TGF-β1 and partial normalization
following the treatment with LY294002 or Akt-DN plasmid. Panels F, F1-F3: Bar graphs represent the density of relative bands of Western blots.
Values are the mean ± SEM, n = 3, * p <0.01 vs. control, # p <0.01 vs.TGF-β1.
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Figure 7 Role of Smurf2 and USP4 in TGF-β1 or Akt-mediated ZO-1, Vimentin and Fibronectin expression in HPMCs. Panels A & B: The
bar graphs represent the summary of the mRNA expression of ZO-1 and Vimentin, as detected by Real-Time PCR. Panel C: Western blot analyses
indicated a decreased protein expression of ZO-1 in HPMCs treated with TGF-β1 or co-transfected with Flag-Akt. There was no obvious change in
cells treated with Smurf2-siRNA and USP4 siRNA compared to basal levels. The TGF-β1-mediated reduced expression of ZO-1 was partially reversed
with the transfection of Smurf2-siRNA and USP4 siRNA. ZO-1 expression was markedly decreased by the treatment with TGF-β1 and transfection with
Flag-Akt. The Smurf2-siRNA and USP4 siRNA also partially restored the TGF-β1 + Flag-AKT reduced ZO-1 mRNA expression. Panel D, D1-D2:
The bar graphs represent the Western blot relative band density of ZO-1 and Vimentin compared to β-actin. Panel E: Bar graphs represent
the fibronectin concentration in the supernatant of cultured HPMCs, as detected by ELISA. Values are the mean ± SEM, n = 4, *p < 0.01 vs control.
# p <0.01 vs TGF-β1, $ p <0.01 vs TGF-β1+ Flag-Akt.
Xiao et al. BMC Cell Biology  (2015) 16:7 Page 10 of 17Effect of TGF-β1, Akt and USP4 on TβR-1, Smad7 and
smurf2 expression and the interaction between Smurf2
and Smad7 as well as TβR-1
Western blot analyses showed that the TβR-1 expression
was significantly increased in HPMCs treated with TGF-
β1 and Flag-Akt (Figure 8A and 8B, B1, lanes 2 & 5 vs
lane 1), whereas no change was seen in cells treated with
Smurf2 siRNA or USP4 siRNA (Figure 8A and 8B, B1,
lanes 3 & 4 vs lane 1). TGF-β1 up-regulated expression
of TβR-1 was further enhanced by treatment with
Smurf2 siRNA and Flag-Akt plasmid (Figure 8A and 8B,B1, lanes 6 & 8 vs lane 2), while it was reduced by USP4
siRNA (lane 7 vs lane 2). In addition, TGF-β1 plus Flag-
Akt increased TβR-1 expression was augmented with the
co-transfection of Smurf2 siRNA (Figure 8A top panels
and 8B, B1, lane 9 vs lane 8). It was also noted that Smad7
protein levels decreased in HPMCs treated with TGF-β1
or Flag-Akt plasmid. No change was seen in Smurf2
siRNA or USP4 siRNA. TGF-β1 decreased Smad7 expres-
sion, and it was partially reversed by the pre-treatment of
smurf2 siRNA or USP4 siRNA. The TGF-β1 decreased
Smad7 expression was little bit further reduced by co-
Figure 8 Expression of TβR-1, Smad7 and Smurf2 in HPMCs stimulated by TGF-β1 and treated with Akt, Smurf siRNA and USP4 siRNA.
Panel A: Western blot profiles of TβR-1, Smad7 and Smurf2 following various treatments as indicated. The β-actin served as a loading control.
Panel B: The bar graphs represent the relative density of the TβR-1 (B1), Smurf2 (B2) and Smad7 (B3) Western blots bands relative to β-actin.
Treatment of TGF- β1 or over-expression of Akt (Flag-Akt) enhances the TβR-1 and Smurf2 protein expression, while it reduces the Smad7 expression.
A concomitant treatment and over-expression further enhances their expression. No change is seen in cells treated with Smurf2 siRNA or USP4 siRNA
alone. The TGF-β1+ Flag Akt-induced Smurf2 expression was slightly reduced by Smurf2-siRNA and not by USP4-siRNA. The Smad7 expression
is reduced with TGF-β1 or Flag-Akt individually, and it is slightly reversed by Smurf2 siRNA. Panel C: Immunoprecipitation/Western blot analyses
represent changes seen in interactions between Smurf2 & Smad7, and Smurf2 & TβR-1 (upper panels). The Smurf2 expression served as loading
controls (bottom panels). Values are the mean ± SEM, n = 3, *p <0.01 versus control, #p <0.01 vs. TGF-β1, $p <0.01 vs. TGF-β1+ Flag-Akt.
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Smad7 expression, and it was partially blocked by either
co-transfection with Smurf2 siRNA or USP4 siRNA
(Figure 8A, and 8B, B2). In addition, there were no signifi-
cant differences in Smurf2 expression between cells
treated with TGF-β1+ Flag-Akt and TGF-β1+ Flag-Akt +
USP4 siRNA. Almost opposite results were seen for
Smad7 protein expression compared to the Smurf2 ex-
pression profiles following various treatments (Figure 8A
middle panels, and 8B, B3).
The immunoprecipitation/Western blot (IP/WB) assay
revealed an increased signal representing the interaction
between Smurf2 and Smad7 in HPMCs following TGF-
β1 treatment (Figure 8C, C1, lane 2 vs lane 1). However,
the signal was significantly reduced with the transfection
of Akt-DN (lane 3 vs lane 2). On the other hand, TGF-β1reduced the association between Smurf2 and TβR-1, while
it was restored by treatment with USP4 siRNA (Figure 8C,
C2, upper panels). Smurf2 expression by IP/WB revealed
no significant change, and Smurf2 served as loading con-
trol (Figure 8C, C1 & C2, lower panels).
Discussion
The observations made in this investigation suggest a
relevance of Akt with respect to the pathology of Meso-
thelial Mesenchymal Transition/Transformation (MMT)
in human peritoneal mesothelial cells (HPMCs) and
peritoneal fibrosis in mice undergoing peritoneal dialysis
(PD). We demonstrated that Akt modulates TGF-β1-
induced MMT and peritoneal fibrosis in PD via down-
stream interactive signaling molecules, such as, Smurf2
and Smad7, and USP4 and TβR-1.
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(EMT), a prototype of MMT, is a complex and gener-
ally reversible process that plays an important role in
embryogenesis, metastasis of malignant cells and tissue
fibrosis [23,24]. During peritoneal dialysis, mesothelial
cells undergo EMT/ MMT associated with peritoneal-
membrane injury. Conceivably, blocking MMT by
Tamoxifen in the PD animal model can ameliorate
peritoneal membrane damage [25]. MMT could lead to
peritoneal fibrosis and peritoneal membrane dysfunc-
tion during long-term PD [26]. Recent studies have
shown that a large number of factors involved in the
process of MMT in PD. Consensus from various studies
are that TGF-β1 is a critical inducer in MMT and fibrosis
in PD [27]. Previously, we demonstrated that TGF-β1 in-
duced EMT in human peritoneal mesothelial cells
(HPMCs) [28]. Here, we extended our studies in animal
models and demonstrated that MMT is associated with
some of the ECM proteins, such as fibronectin and fibro-
sis in the peritoneum of mice undergoing PD (Figure 2A-
D). Consistent with this was thickening of sub-mesothelial
tissues and up-regulation of TGF-β1 in PD effluent
(Figure 1A). In addition, the in vitro studies confirmed
that TGF-β1 is capable of inducing the MMT-relevant
proteins expression in HPMCs (Figures 3A, 3B, 4A, 4B,
4D and 4E). The expression of these proteins seems to
be modulated by increased or reduced expression of
Akt with TGF-β1 being the upstream regulator. Our
results are consistent with previous reports indicating
inhibiting TGF-β1 signaling ameliorates experimental
peritoneal fibrosis [29]. These studies also implicated
that Akt could play a critical role in TGF-β1 induced
MMT and peritoneal fibrosis in PD, although detailed
mechanisms pertaining to mesothelial pathobiology
remained to be work out. Much of the work in this regard
has been focused on tubular epithelial cell biology.
Emerging evidence shows that the PI3K/Akt pathway
is another non-Smad pathway contributing to TGF-β in-
duced EMT [30]. PI3K/Akt modulates TGF-β1-induced
EMT in renal tubular cells [12]. TGF-β apparently
causes phosphorylation of Akt, which seems to be re-
quired for TGF-β-induced EMT [31]. Moreover,
LY294002, an inhibitor of PI3K/Akt, can attenuate
insulin-induced PI3 kinase-dependent Akt phosphoryl-
ation and reduce apoptosis in peritoneal mesothelial
cells [32]. Treatment with LY294002 also significantly
reduces TGF-β1-stimulated COL1A2 promoter activity
and expression, as well as diminishes the effect of VEGF
and thus conceivably inhibits EMT transformation in
renal tubular epithelial cells [33,34]. Furthermore, TGF-β
induced down-regulation of E-cadherin in renal tubular
epithelial cells has been reported following the treatment
with LY294002, suggesting that Akt may play a key role in
TGF-β induced EMT transformation [35]. In addition,PI3K/Akt pathway regulates TGF-β signaling cascade by
inducing Smad7 expression [36]. However, whether Akt is
involved in the process of TGF-β induce MMT in PD by
modulating the pathobiology of mesothelial cells is uncer-
tain. Also, the mechanisms by which Akt mediates MMT
coupled fibrosis in PD or by TGF-β1 stimulating peri-
toneal mesothelial cells have not been so far clearly
delineated.
Certainly, it is known that TGF-β family members trans-
duce signals through membrane serine/threonine kinase
receptors and intracellular Smad proteins including
Smad2/3 which are regulated by Smad7 via E3 ubiquitin
ligases, such as, Smurf2 [37]. In addition, TGF-β stimu-
lates Smurf2 promoter activity and its expression by a
Smad-independent pathway, such as, the PI3K/Akt
pathway [13]. Smurf2 contains three WW domains,
which can bind to the Smad7 PY motif region and form
a complex [38]. After Smurf2 binding to Smad7 it is
exported to the membrane of cells, where it causes deg-
radation of Smad7 and TGB-β1 receptor [39]. Further-
more, in the presence of TGF-β Signaling the degradation
of Smad7 is dependent on the catalytic activity of the
Smurf2 HECT domain [40]. Recently, Tan RY et al. found
that Smurf2 expression is significantly increased upon
TGF-β1 stimulation, and over-expression of Smurf2 aug-
mented TGF-β1-mediated E-cadherin suppression in hu-
man tubular epithelial cells [41]. On the other hand,
Smad7 negatively regulates the TGF-β1/Smad pathway
[42,43]. Overexpression of Smad7 has been shown to in-
hibit AngII-induced TGF-β/Smad activation and EMT in
NRK52E cells and in a rat model of remnant kidney dis-
ease [44]. Interestingly, transfer of Smad7 gene by ultra-
sound microbubble method into the peritoneum inhibits
Smad2/3 activation, decreases α-SMA expression, and at-
tenuates peritoneal fibrosis in a rat model of PD [45].
Taken together the data of above indicated studies, it
seems that the activation of TGF-β1-Akt-Smurf2-Smad7
pathway may mediate MMT in PD. Thus, we hypothe-
sized that activation of Akt by TGF-β1 increases Smurf2
expression which would inhibit Smad7, and thus Akt
could participate in TGF-β1-induced MMTand peritoneal
fibrosis in mice undergoing PD.
To address all these myriad of issues, in vivo and
in vitro studies were carried out in PD mice model and
HPMCs by the multitude of methods, including tissue
morphology, Real Time PCR, immunohistochemistry
and Western blot analyses. We observed that the expres-
sion and activity of pAkt and Smurf2 were increased in
the peritoneum of PD mice while Smad7 was decreased
(Figure 1B-1C). In addition, pAkt expression rapidly
increased in the nuclear compartment in a dose-
dependent manner in HPMCs subjected to TGF-β1
(Figure 4D and 4F), which was accompanied with al-
tered of Smurf2, Smad7 and MMT-relevant proteins’
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of Smurf2, Smad7 and EMT relevant proteins in the
peritoneum of PD mice was reversed following in vivo
treatment with LY294002 (Figure 1D), and so was case
when TGF-β1-induced HPMCs were treated in vitro
with LY294002 or transfected with Flag-Akt or Akt-
DN expression plasmids (Figures 5, 6 and 7). These ob-
servations clearly indicate that the activation of pAkt
induces MMT transformation during PD and it medi-
ated via the increased expression of Smurf2 with sim-
ultaneous down-regulation of Smad7.
The next question that needs to be addressed pertains
to the status of TGF-β1 receptor during MMT trans-
formation. TGF-β signaling pathway is tightly regulated
through protein ubiquitination, e.g., TRβ1 degradation. It
is known that levels of TβRI at the cell surface are regu-
lated by Smurf 2/Smad7 complex, and the stability of
this receptor determines the status of TGF-β signaling
[40]. In this regard, it has been shown that the treatment
with TβR-I inhibitor suppresses the lymphangiogenesis
and VEGF-C expression in a murine model of peritoneal
fibrosis [46]. With respect to TβR-I pathobiology, exten-
sive studies carried out in the past in a vast number of
systems indicate that there is a crosstalk between PI3K/
Akt and TGF-β signaling pathways, which at times
counteract while in other situations cooperate with one
another [47]. Recently Eichhorn et al. using a functional
RNAi screen identified the deubiquitinating enzyme
ubiquitin-specific protease 15 (USP15) as a key compo-
nent of the TGF-β signaling pathway [21]. USP15 binds
to Smurf2 complex and deubiquitinates and stabilizes
TRβ1, and that apparently leads to boosting of TGF-β-
mediated signaling. Likewise USP4 as a deubiquitylating
enzyme also interacts with TβRI at the plasma mem-
brane and reverses its ubiquitination and thus regulates
the TβRI levels [16]. Conceivably, AKT directly interacts
with USP4 for its phosphorylation and translocates nu-
clear USP4 to the membrane and thus maintains TβRI
stability and possibly modulates TGF-β induced EMT/
MMT.
In reference to the role of Smurf2 and USP4 in MMT
in PD. our data indeed show that there is some modula-
tion by the Akt in downstream signaling. To verify the
effect of Akt regulation on MMT in PD, Smurf2 siRNA
and USP4 siRNA experiments were carried out in
HPMCs. Results showed that inhibition of USP4 and
Smurf2 expression significantly reverses the altered ex-
pression of ZO-1, Vimentin and TβRI induced by TGF-
β1, while overexpression of Akt augments these effects.
Transfection with USP4 siRNA or Smurf2 siRNA also
inhibited the effect exerted by TGFβ1+ Akt on the ex-
pression of TβRI, ZO-1 and Vimentin (Figures 7 and 8).
Additionally, to address the issue that whether Akt and
USP4 regulate the interaction between Smurf2 andSmad7, and Smurf2 and TβRI induced by TGF-β1, im-
munoprecipitation/Western blot assays were carried
out. They revealed that Akt-DN and USP4 siRNA can
disrupt their association in HPMCs treated with TGF-
β1 (Figure 8D). This indicated that Akt may regulate
MMT in PD via various signaling pathways which in-
volve the Smurf2/USP4/TβRI complex.
Conclusions
The findings of the current study highlights the activa-
tion of Akt mediated EMT/MMT transformation in PD
via Smurf2 modulation/and or Smad7 degradation while
conceivably maintaining the TβRI stability, most likely
by the USP4. The findings also suggest that Akt plays a
central role in MMT and fibrosis during PD through
Smurf2/Smad7 and USP4/TβRI pathway or their inter-
action (Figure 9). It is anticipated that this information
may provide potential therapeutic molecular targets for




Twenty four female mice aged 12 weeks were used. The
mice were housed in standard conditions and with free
access to food and water. A Peritoneal dialysis mouse
model was established according to the report by
Aroeira LS et al., as previously described [48]. Briefly, to
prevent obstruction and proper drainage of fluid, cathe-
ters containing ten holes within 1 cm from the tip were
used. Following anesthesia by intra-peritoneal injection
of Ketamine (100 mg/kg) and Xylazine (10 mg/kg), the
end of catheter was introduced into the peritoneal cavity
by the right flank incision, and the port was placed in
the subcutaneous space on the dorsum of the mice. One
week after the surgery, the mice were divided into 3
groups of 20 mice each. In group one (control group),
1.5 ml of physiologic saline was administered (in this
group, 5 mice were sacrificed on day 0 of the experi-
ment). In the second group (PD group), the mice were
administered daily 1.5 ml of standard PD fluid contain-
ing 4.25% glucose. In the third group (PD + LY group),
the mice were administered daily 1.5 ml of standard PD
fluid containing 4.25% glucose followed by intra-peritoneal
injections of the PI3K/Akt inhibitor, LY294002 (25 mg/kg
in 35% DMSO, Sigma). The inhibitor was administered
twice a week for 4 weeks, as previously described [49]. All
mice were sacrificed at 4 weeks. To avoid injury to the
peritoneum of PD mice group, the peritoneal tissues were
collected from the upper portion of the parietal periton-
eum after sacrificing using 50 mg/kg of pentobarbital so-
dium anesthesia by intra-peritoneal injection, as described
previously [50]. The tissues were then used for various
biochemical and morphological studies. The dialysate in
Figure 9 Schematic drawing depicting the conceivable events following TGF-β1 treatment and activation of Akt. This leads to initiation
of transcription of Smuf2 and degradation of Smad7 and phosphorylation of USP4 while maintaining the TβRI stability. Finally, this results in the
induction of MMT of mesothelial cells and fibrosis during peritoneal dialysis.
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ous ELISA assays. The animal experiments were approved
by the Animal Care and Use Committee of Second Xiangya
Hospital of Central South University, Changsha, China.
Histological and immunofluorescence analysis
For tissue analysis, 4 μm thick paraffin sections from the
anterior abdominal wall were taken and processed for
Hematoxylin-Eosin (HE) and Masson’s trichrome stain-
ing. The thickness of the sub-mesothelial tissue was de-
termined by microscope using a metric ocular; and it
was expressed as the mean of 10 independent readings
for each mouse section as ref [51]. For confocal imaging
analysis, 6 μm thick paraffin sections were pretreated
with citrate buffer (10 mM, pH 6.0) for 15 min at 37°C
and then incubated with various indicated antibodies at
4°C overnight. Sections were then immuno-stained with
FITC-labeled secondary antibodies. The sections were
cover-slip mounted and examined with a Zeiss fluores-
cence microscope.
Cell culture studies
HMrSV5, a human peritoneal mesothelial cell line
(HPMC) [19,20] was a gift from Pierre M Ronco (TenonHospital, Paris), and it was maintained in low glucose
DMEM medium supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin, and 100 mg/ml
streptomycin. To study the dose- and time-course effect
of TGF-β1 on MMT of HPMCs and the expression of
pAkt, Smurf2 and Smad7, 0–10 ng/ml TGF-β1 (R&D
Systems) was added at different intervals as indicated
(0–72 hrs). To examine the role of Akt in MMT trans-
formation, Smad7 and Smurf2 expression of HPMCs,
LY294002 (10–20 μg/ml, Calbiochem) was used to pre-
treat the cells for 30 min or they were pre-transfected
with a dominant negative Akt mutant (K179M) plasmid
(Akt-DN, Addgene) for 24 hrs and then the cells were
exposed to TGF-β1 (5 ng/ml) for 24–48 hrs.
To investigate the effect of Smurf2 and USP4 on
MMT transformation of HPMCs, HPMCs were trans-
fected with Smurf2 siRNA (Ambion), USP4 siRNA (Santa
Cruz Biotech), respectively, with or without pWZL Neo
Myr Flag AKT1 (Flag Akt plasmid) which is part of a
kinase library, and has constitutively active expression
(Biovector – Addgene, Plasmid 20422) for 24 hrs. To
assess the effect of Akt, Smurf2 and USP4 on TβRI ex-
pression, Flag-Akt plasmid, Smurf2 siRNA and USP4
siRNA were used. Cells were transfected with various
Table 1 Real-time PCR primer sequences
Primer Name Primer Sequence
Human Zo-1 (134 bp) Sense 5′ TGGTGTCCTACCTAATTCAACTCA 3′
Antisense 5′ CGCCAGCTACAAATATTCCAACA 3′
Mice Zo-1 (97 bp) Sense 5′ CGAGGCATCATCCCAAATAAGAAC 3′
Antisense 5′ TCCAGAAGTCTGCCCGATCAC 3′
Human Vimentin (136 bp) Sense 5′ TTGAACGCAAAGTGGAATC 3′
Antisense 5′ AGGTCAGGCTTGGAAACA 3′
Mice Vimentin (196 bp) Sense 5′ ACCGCTTTGCCAACTACAT 3′
Antisense 5′ TTGTCCCGCTCCACCTC 3′
Human fibronectin (238 bp) Sense 5′ TACCCTTCCACACCCCAATC 3′
Antisense 5′ CGGGTATGGTCTTGGCCTAT 3′
Mice fibronectin (184 bp) Sense 5′ TCTCGGAGCCATTTGTTCCT3′
Antisense 5′ GAAGCACTCAATGGGGCAAT3′
Human smurf2 (206 bp) Sense 5′ TAGCCCTGGCAGACCTCTT 3′
Antisense 5′ CTTGTTGCGTTGTCCTCTGT 3′
Mice smurf2 (114 bp) Sense 5′ GTGAAGAGCTCGGTCCTTTG 3′
Antisense 5′ AGAGCCGGGGATCTGTAAAT 3′
Human β-actin (125 bp) Sense 5′ AGATGTGGATCAGCAAGCAG 3′
Antisense 5′ GCGCAAGTTAGGTTTTGTCA 3′
Mice β-actin (125 bp) Sense 5′ AGATGTGGATCAGCAAGCAG 3′
Antisense 5′ GCGCAAGTTAGGTTTTGTCA 3′
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mendations where Lipofectamine 2000 Reagent (Invi-
trogen) was employed. The cells were exposed to TGF-
β1 for another 48 hrs. The treated cells were processed
for determining their protein expression.
Immunofluorescence analysis
HPMCs were grown on cover-slips, washed twice with
PBS, fixed in 4% paraformaldehyde for 20 min and
permeabilized using 0.1% Triton X-100. Anti-ZO-1
(1:100 dilution, Santa Cruz), anti-Vimentin (1:100, Santa
Cruz), anti-pAkt (1:80, Cell Signaling) and anti-Smurf2
(1:80, Santa Cruz) antibodies were diluted in a blocking
buffer and incubated with cells overnight at 4°C. The
cover-slips containing the cells were washed with PBS 3
times, followed by incubation with FITC-labeled second-
ary antibodies (Santa Cruz) for 2 hrs at 22°C. The cells
were then examined using a fluorescence microscope.
Enzyme-Linked Immunosorbent Assay (ELISA)
Total TGF-β1 protein was determined in PD effluent
from the various experimental groups using the Quanti-
kine Immunoassay (R&D Systems, Minneapolis, MN).
Fibronectin in the supernatant of cultured HPMCs was
measured by the Quantimatrix human fibronectin
enzyme-linked immunosorbent assay kit (ELISA) from
Chemicon International (Temecula, CA), as described
previously [52].
Real-time Polymerase Chain Reaction (Real-time PCR)
Total RNAs of HPMCs cells and peritoneal tissues were
isolated by using Trizol kit (Invitrogen). First-strand
cDNAs were generated by two-step RT-PCR (Fermentas
Life Science). Real-time PCR was performed using Ap-
plied Biosystems 7300 Real-time PCR System and a
SYBRgreen PCR reagent kit (Invitrogen). Total RNA was
reverse-transcribed and subjected to PCR. The protocol
included 94°C for 2 min followed by 40 cycles of the fol-
lowing: 94°C for 15 seconds, 58°C for 30 seconds and
72°C for 30 seconds, and a final extension cycle at 72°C
for 10 min. The primer sets used for the various genes
are included in Table 1.
Nuclear extraction
HPMCs cells were harvested in Phosphate Buffered
Saline (PBS), washed twice with cold PBS and then re-
suspended in 500 μl hypotonic Buffer (20 mM Tris–
HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2). They were in-
cubated on ice for 15 min, 50 μl of NP40 added and vor-
texed for 10 sec. The homogenate was centrifuged at
1,000 × g for 10 min at 4°C. The pellet was designated
as the nuclear fraction. The pellet was lysed in 50 μl
RIPA buffer (25 mM Tris, pH 7.6, 0.15 M NaCl, 1% NP-
40, 1% sodium deoxycholate and 0.1% SDS) containingprotease inhibitors. The lysate was centrifuged at 14,000
× g for 30 min, at 4°C. The supernatant was used for
Western blot analyses.
Western blot analysis
Western blot analyses were performed as described pre-
viously [7]. Briefly, samples (20 μg protein) were sub-
jected to SDS–PAGE. The proteins were transferred
onto nitrocellulose membranes, which were probed with
the specific antibodies: anti-ZO-1, anti-vimentin, anti-
Smad7 and anti-Smurf2 (Santa Cruz, 1:1000), anti-pan-
Akt (phospho T308) antibody (Abcam) also known as
anti-pAkt, anti-total Akt, (Cell Signaling, 1:1000) and
anti-FN (BD Biosciences, 1:1000). A peroxidase-
conjugated goat anti mouse IgG (1: 10 000) was used as
a secondary antibody. For detection of other proteins or
β-actin, the membranes were treated with Stripping buf-
fer and then re-probed with another antibody or β-actin
antibody, the latter served as an internal control.
Immunoprecipitation/ Western blotting studies with
Smurf2 and Smad7
Cell lysates were individually incubated with anti-smurf2
or anti-Smad7 antibody in an IP buffer for 12 hrs at 4°C
with gentle orbital rotation. 50 μl of protein A-
Sepharose beads were added, and the incubation was
Xiao et al. BMC Cell Biology  (2015) 16:7 Page 16 of 17extended for another 12 hrs. The beads were washed
with the IP buffer and resuspended in SDS loading buf-
fer, and then the entire sample was subjected to 10%
SDS-PAGE followed by Western blotting procedures.
Statistics
Data were expressed as the mean ± SD, and one-way
analysis of variance (ANOVA) was carried out. P <0.05
was considered statistically significant.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LX and XP generated the data and performed the statistical analysis and
helped to draft the manuscript. FYL, CYT, CH, XXX, MW, YL and SKY
generated the data for the manuscript. PAS and PX edited the manuscript
and guided the statistical analysis and discussed the results of the
manuscript. YSK and LS conceived of the study, participated in its design,
coordination and wrote the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
This work was supported by grants from the Creative Research Group Fund
of the National Foundation Committee of Natural Sciences of China
(81100541, 81370832 and 81270812), the Doctoral Fund of Ministry of
Education of China (20110162110012), the Furong Scholars Fund from
Hunan Province Education Department, and USA NIH grant (DK60635).
Author details
1Department of Nephrology, Second Xiangya Hospital, Central South
University, Changsha, Hunan 410011, China. 2Departments of Pathology &
Medicine, Northwestern University, Chicago, USA.
Received: 19 June 2014 Accepted: 19 February 2015
References
1. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C,
Jimenez-Heffernan JA, et al. Peritoneal dialysis and epithelial-to-mesenchymal
transition of mesothelial cells. N Engl J Med. 2003;348:403–13.
2. Davenport A. Portable or wearable peritoneal devices–the next step forward
for peritoneal dialysis? Adv Perit Dial. 2012;28:97–101.
3. Zhang H, Liu X, Liu Y, Yi B, Yu X. Epithelial-mesenchymal transition of rat
peritoneal mesothelial cells via Rhoa/Rock pathway. In Vitro Cell Dev Biol
Anim. 2011;47:165–72.
4. Liu Q, Mao H, Nie J, Chen W, Yang Q, Dong X, et al. Transforming growth
factor β1 induces epithelial-mesenchymal transition by activating the
JNK-Smad3 pathway in rat peritoneal mesothelial cells. Perit Dial Int.
2008;28:S88–95.
5. Loureiro J, Aguilera A, Selgas R, Sandoval P, Albar-Vizcaino P, Pérez-Lozano
ML, et al. Blocking TGF-β1 protects the peritoneal membrane from
dialysate-induced damage. J Am Soc Nephrol. 2011;22:1682–95.
6. Lin CC, Chiang LL, Lin CH, Shih CH, Liao YT, Hsu MJ, et al. Transforming
growth factor-beta1 stimulates heme oxygenase-1 expression via the
PI3K/Akt and NF-kappaB pathways in human lung epithelial cells. Eur J
Pharmacol. 2007;560:101–9.
7. Yao K, Ye PP, Tan J, Tang XJ, Shen Tu XC. Involvement of PI3K/Akt pathway
in TGF-beta2-mediated epithelial mesenchymal transition in human lens
epithelial cells. Ophthalmic Res. 2008;40:69–76.
8. Yi JY, Shin I, Arteaga CL. Type I transforming growth factor beta receptor
binds to and activates phosphatidylinositol 3-kinase. J Biol Chem.
2005;280:10870–6.
9. Runyan CE, Schnaper HW, Poncelet AC. The phosphatidylinositol 3-kinase/
Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression
in response to transforming growth factor-beta1. J Biol Chem.
2004;279:2632–9.
10. Chen XF, Zhang HJ, Wang HB, Zhu J, Zhou WY, Zhang H, et al.
Transforming growth factor-β1 induces epithelial-to-mesenchymal transitionin human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways.
Mol Biol Rep. 2012;39:3549–56.
11. Ogunwobi OO, Wang T, Zhang L, Liu C. Cyclooxygenase-2 and Akt mediate
multiple growth-factor-induced epithelial-mesenchymal transition in human
hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:566–78.
12. Lee YJ, Han HJ. Troglitazone ameliorates high glucose-induced EMT and
dysfunction of SGLTs through PI3K/Akt, GSK-3β, Snail1, and β-catenin in
renal proximal tubule cells. Am J Physiol Renal Physiol. 2010;298:F1263–75.
13. Ohashi N, Yamamoto T, Uchida C, Togawa A, Fukasawa H, Fujigaki Y, et al.
Transcriptional induction of Smurf2 ubiquitin ligase by TGF-beta. FEBS Let.
2005;579:2557–63.
14. Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, Oda T, et al.
Down-regulation of Smad7 expression by ubiquitin-dependent degradation
contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl
Acad Sci U S A. 2004;101:8687–92.
15. Cai Y, Zhou CH, Fu D, Shen XZ. Overexpression of Smad ubiquitin
regulatory factor 2 suppresses transforming growth factor-β mediated liver
fibrosis. J Dig Dis. 2012;13:327–34.
16. Aggarwal K, Massague J. Ubiquitin removal in the TGF-β pathway. Nat Cell
Biol. 2012;14:656–7.
17. Peng W, Dou X, Hao W, Zhou Q, Tang R, Nie J, et al. Smad7 gene transfer
attenuates angiogenesis in peritoneal dialysis rats. Nephrology. Nephrology
(Carlton). 2013;18:138–47.
18. Guo H, Leung JC, Lam MF, Chan LY, Tsang AW, Lan HY, et al. Smad7
transgene attenuates peritoneal fibrosis in uremic rats treated with
peritoneal dialysis. J Am Soc Nephrol. 2007;18:2689–703.
19. Nie J, Dou X, Hao W, Wang X, Peng W, Jia Z, et al. Smad7 gene transfer
inhibits peritoneal fibrosis. Kidney Int. 2007;72:1336–44.
20. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-
mediated negative regulation of TGF-beta signaling in scleroderma
fibroblasts. J Clin Invest. 2004;113:253–64.
21. Eichhorn PJ, Rodon L, Gonzalez-Junca A, Dirac A, Gili M, Martinez-Saez E,
et al. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through
the activation of TGF-β signaling in glioblastoma. Nat Med. 2012;18:429–35.
22. Zhang L, Zhou F, Drabsch Y, Gao R, Snaar-Jagalska BE, Mickanin C, et al.
USP4 is regulated by AKT phosphorylation and directly deubiquitylates
TGF-β type I receptor. Nat Cell Biol. 2012;14:717–26.
23. Xue C, Plieth D, Venkov C, Xu C, Neilson EG. The gatekeeper effect of
epithelial-mesenchymal transition regulates the frequency of breast cancer
metastasis. Cancer Res. 2003;63:3386–94.
24. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in
renal fibrosis. J Mol Med (Berl). 2004;82:175–81.
25. Loureiro J, Sandoval P, del Peso G, Gonzalez-Mateo G, Fernandez-Millara V,
Santamaria B, et al. Tamoxifen ameliorates peritoneal membrane damage
by blocking mesothelial to mesenchymal transition in peritoneal dialysis.
PLoS One. 2013;8:e61165.
26. Aroeira LS, Aguilera A, Sanchez-Tomero JA, Bajo MA, del Peso G, Jiménez-
Heffernan JA, et al. Epithelial to mesenchymal transition and peritoneal
membrane failure in peritoneal dialysis patients: pathologic significance and
potential therapeutic interventions. J Am Soc Nephrol. 2007;18:2004–13.
27. Liu Q, Zhang Y, Mao H, Chen W, Luo N, Zhou Q, et al. A crosstalk between
the Smad and JNK signaling in the TGF-β-induced epithelial-mesenchymal
transition in rat peritoneal mesothelial cells. PLoS One. 2012;7:e32009.
28. Zhang K, Zhang H, Zhou X, Tang WB, Xiao L, Liu YH, et al. miRNA589
regulates epithelial-mesenchymal transition in human peritoneal mesothelial
cells. J Biomed Biotechnol. 2012;2012:673096.
29. Ueno T, Nakashima A, Doi S, Kawamoto T, Honda K, Yokoyama Y, et al.
Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by
suppressing inflammation and inhibiting TGF-β1 signaling. Kidney Int.
2013;84:297–307.
30. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19:128–39.
31. Bakin AV, Tomlinson AK, Bhowmick NA, Moses H, Arteaga CL.
Phosphatidylinositol 3-kinase function is required for transforming growth
factor beta-mediated epithelial to mesenchymal transition and cell migra-
tion. J Biol Chem. 2000;275:36803–10.
32. Kaifu K, Kiyomoto H, Hitomi H, Matsubara K, Hara T, Moriwaki K, et al. Insulin
attenuates apoptosis induced by high glucose via the PI3-kinase/Akt pathway
in rat peritoneal mesothelial cells. Nephrol Dial Transplant. 2009;24:809–15.
33. Hubchak SC, Sparks EE, Hayashida T, Schnaper HW. Rac1 promotes TGF-beta-
stimulated mesangial cell type I collagen expression through a PI3K/Akt-
dependent mechanism. Am J Physiol Renal Physiol. 2009;297:F1316–23.
Xiao et al. BMC Cell Biology  (2015) 16:7 Page 17 of 1734. Hong JP, Li XM, Li MX, Zheng FL. VEGF suppresses epithelial-mesenchymal
transition by inhibiting the expression of Smad3 and miR192, a
Smad3-dependent microRNA. Int J Mol Med. 2013;31:1436–42.
35. Deng B, Yang X, Liu J, He F, Zhu Z, Zhang C. Focal adhesion kinase mediates
TGF-beta1-induced renal tubular epithelial-to-mesenchymal transition in vitro.
Mol Cell Biochem. 2010;340:21–9.
36. Band AM, Bjorklund M, Laiho M. The phosphatidylinositol 3-kinase/Akt pathway
regulates transforming growth factor-{beta} signaling by destabilizing ski and
inducing Smad7. J Biol Chem. 2009;284:35441–9.
37. Inoue Y, Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin
ligases. Cancer Sci. 2008;99:2107–12.
38. Chong PA, Lin H, Wrana JL, Forman-Kay JD. An expanded WW domain
recognition motif revealed by the interaction between Smad7 and the E3
ubiquitin ligase Smurf2. J Biol Chem. 2006;281:17069–75.
39. Aragon E, Goerner N, Xi Q, Gomes T, Gao S, Massague J, et al. Structural
basis for the versatile interactions of Smad7 with regulator WW domains in
TGF-β Pathways. Structure. 2012;20:1726–36.
40. Bizet AA, Tran-Khanh N, Saksena A, Liu K, Buschmann MD, Philip A.
CD109-mediated degradation of TGF-β receptors and inhibition of TGF-β
responses involve regulation of SMAD7 and Smurf2 localization and
function. J Cell Biochem. 2012;113:238–46.
41. Tan R, He W, Lin X, Kiss LP, Liu Y. Smad ubiquitination regulatory factor-2 in
the fibrotic kidney: regulation, target specificity, and functional implication.
Am J Physiol Renal Physiol. 2008;294:F1076–83.
42. Liu GX, Li YQ, Huang XR, Wei L, Chen HY, Shi YJ, et al. Disruption of Smad7
promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-β/
Smad3-NF.κB-dependent mechanisms in mice. PLoS One. 2013;8:e53573.
43. Lan HY. Smad7 as a therapeutic agent for chronic kidney diseases. Front
Biosci. 2008;13:4984–92.
44. Yang F, Huang XR, Chung AC, Hou CC, Lai KN, Lan HY. Essential role for
Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition.
J Pathol. 2010;221:390–401.
45. Nie J, Hao W, Dou X, Wang X, Luo N, Lan HY, et al. Effects of Smad7
overexpression on peritoneal inflammation in a rat peritoneal dialysis
model. Perit Dial Int. 2007;27:580–8.
46. Kinashi H, Ito Y, Mizuno M, Suzuki Y, Terabayashi T, Nagura F, et al. TGF-β1
promotes lymphangiogenesis during peritoneal fibrosis. J Am Soc Nephrol.
2013;24:1627–42.
47. Zhang L, Zhou F, ten Dijke P. Signaling interplay between transforming
growth factor-β receptor and PI3K/AKT pathways in cancer. Trends Biochem
Sci. 2013;38:612–20.
48. Aroeira LS, Loureiro J, Gonzalez-Mateo GT, Fernandez-Millara V, del Peso G,
Sánchez-Tomero JA, et al. Characterization of epithelial-to-mesenchymal
transition of mesothelial cells in a mouse model of chronic peritoneal
exposure to high glucose dialysate. Perit Dial Int. 2009;5:S29–33.
49. LinY SZ. Thyroid hormone potentiates insulin signaling and attenuates
hyperglycemia and insulin resistance in a mouse model of type 2 diabetes.
Br J Pharmacol. 2011;162:597–610.
50. Yokoi H, Kasahara M, Mori K, Ogawa Y, Kuwabara T, Imamaki H, et al.
Pleiotrophin triggers inflammation and increased peritoneal permeability
leading to peritoneal fibrosis. Kidney Int. 2012;81:160–9.
51. Yu JW, Duan WJ, Huang XR, Meng XM, Yu XQ, Lan HY. MicroRNA-29b inhibits
peritoneal fibrosis in a mouse model of peritoneal dialysis. Lab Invest.
2014;94:978–90.
52. Weigert C, Brodbeck K, Brosius FC, Huber M, Lehmann R, Friess U, et al.
Evidence for a novel TGF-beta1-independent mechanism of fibronectin
production in mesangial cells overexpressing glucose transporters. Diabetes.
2003;52:527–35.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
